Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA. Rubin EH, et al. Among authors: chaudhary a. Clin Cancer Res. 2002 Dec;8(12):3710-7. Clin Cancer Res. 2002. PMID: 12473580 Clinical Trial.
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA. Sandler A, et al. Among authors: chaudhary a. Clin Cancer Res. 2004 May 15;10(10):3265-72. doi: 10.1158/1078-0432.CCR-03-0644. Clin Cancer Res. 2004. PMID: 15161679 Clinical Trial.
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, Seymour L. Lê LH, et al. Among authors: chaudhary a. Cancer Chemother Pharmacol. 2005 Aug;56(2):154-60. doi: 10.1007/s00280-004-0942-7. Epub 2005 Apr 5. Cancer Chemother Pharmacol. 2005. PMID: 15809877 Clinical Trial.
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH, Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A, Mita AC, Rowinsky EK. Sweeney CJ, et al. Among authors: chaudhary ak. Clin Cancer Res. 2006 Jan 15;12(2):536-42. doi: 10.1158/1078-0432.CCR-05-1834. Clin Cancer Res. 2006. PMID: 16428497 Clinical Trial.
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Mita AC, et al. Among authors: chaudhary ak. J Clin Oncol. 2006 Feb 1;24(4):552-62. doi: 10.1200/JCO.2004.00.9720. Epub 2006 Jan 3. J Clin Oncol. 2006. PMID: 16391300 Clinical Trial.
1,744 results